Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ethicon Opens Up To Chronic Sinusitis Market With $785 Mil. Acclarent Buy

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson/Ethicon will use its $785 million acquisition of Acclarent, developer of the Balloon Sinuplasty system for chronic sinusitis, as a platform for growth in the ear, nose and throat business

You may also be interested in...

Blues’ TEC Delivers Mostly Negative Assessments For Three Technologies

The Blue Cross Blue Shield Technology Evaluation Center considered balloon ostial dilation for the treatment for chronic rhinosinusitis; multianalyte testing for evaluation of adnexal masses; and nucleic acid sequencing-based testing of maternal plasma for fetal aneuploidy.

Cook Medical Plans Rapid Scale-Up Of Newly Launched ENT Unit

Firm unveils a range of new products for minimally invasive treatment of ear, nose and throat conditions Sept. 10 at the American Academy of Otolaryngology-Head and Neck Surgery annual conference in Washington, D.C.

J&J Q2 results

Ethicon sales rose 8.2% to $1.13 billion in the second quarter, driven by sutures, biosurgicals and Mentor aesthetic devices, Johnson & Johnson reported July 20. The acquisition of Acclarent also contributed to growth, the firm noted. J&J bought the Balloon Sinuplasty developer for $785 million in December (1"The Gray Sheet" Dec. 21, 2009). Advanced sterilization and Harmonic ultrasonic devices helped grow Ethicon Endo-Surgery revenues 6.6% to $1.2 billion. The Cordis division continued to struggle, with sales dropping 2.8% to $655 million. Medical devices and diagnostics sales of $6.1 billion were up 3.5% overall

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts